Verastem, Inc. (VSTM)
Chart Events
Performance Outlook
| Previous Close | 2.7600 |
| Open | 3.3200 |
| Bid | 2.7700 x 4000 |
| Ask | 2.7800 x 1400 |
| Day's Range | 2.7200 - 3.5800 |
| 52 Week Range | 1.1400 - 4.9300 |
| Volume | 33,436,199 |
| Avg. Volume | 1,814,574 |
| Market Cap | 509.738M |
| Beta (5Y Monthly) | 0.88 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2260 |
| Earnings Date | Nov 08, 2021 - Nov 12, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.25 |
Fair Value
Related Research
- Verastem, Inc.Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion. Pfizer also spends a leading amount on research and development, close to $8 billion annually. While Pfizer historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.RatingFair ValueEconomic Moat3 days agoMorningstar
- Benzinga
Why Verastem Shares Are Trading Higher Today
Verastem Inc (NASDAQ: VSTM) is trading higher Monday after the company announced updated investigator-sponsored Phase 1/2 FRAME study data of VS-6766 with defactinib in low-grade serous ovarian cancer showing "encouraging response rates and progression-free survival." “The investigator-sponsored FRAME study, the initial results of which led the U.S. Food and Drug Administration (FDA) to grant Breakthrough Therapy designation for the VS-6766 and defactinib combination in LGSOC, continues to be in
- Business Wire
Verastem Oncology and Amgen Partner to Evaluate VS-6766 in Combination with LUMAKRASTM (Sotorasib) in Patients with KRAS G12C-Mutant Non-Small Cell Lung Cancer
BOSTON, September 20, 2021--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced a clinical collaboration agreement with Amgen to evaluate the combination of VS-6766, Verastem Oncology’s investigational dual RAF/MEK inhibitor, with Amgen’s KRAS G12C inhibitor LUMAKRASTM (sotorasib) in KRAS G12C-mutant non-small cell lung cancer (NSCLC).
- Business Wire
Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates and Progression-Free Survival Presented at ESMO 2021
BOSTON, September 19, 2021--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced a mini oral presentation highlighting updated data from the ongoing investigator-sponsored Phase 1/2 FRAME study. The FRAME study, led by The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, is investigating VS-6766, Verastem’s RAF/MEK inhibitor, in combination with defactinib, its FAK inhibitor, i
